EPIVARIO INC

Philadelphia, PA · Founded 2017 · Biotech · Private

Neuroepigenetic modulators targeting memory-related addiction and psychiatric disorders

Claim this profile

Follows are private to you and power your alerts

Updated · epivario.com

Sector
Biotech
Headquarters
Philadelphia, PA
Founded
2017
Latest Form D
$185K, Oct 2026
Total capital
$2M
Federal grants
$1.1M
4 awards · 2022–2024
Rank in peer group#172 of 392
Private capital raised
$883K
5 Form D · last Oct 2026
0 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
3 pending · first 2024
Rank in peer group#53 of 392

Capital timeline

20182020202220242026FEDERAL ↑EQUITY ↓Cumulative $2M$260K$260K$295K$275K1st Form D$205K2nd Form D$233K4th Form D$125K5th Form D$185K
20182020202220242026FEDERAL ↑EQUITY ↓Cumulative $2M$260K$260K$295K$275K2nd Form D$233K5th Form D$185K

Latest events

  • Private capital raisedForm D · SEC · 5th filing$185K
  • Federal grantHealth and Human S · Phase I · Developing a novel epigenetic regulator as a treatment for opioid use disorder$275K
  • Federal grantHealth and Human S · Phase I · Developing a novel epigenetic regulator as a treatment for cocaine use disorder$295K
  • Private capital raisedForm D · SEC · 4th filing$125K
  • Private capital raisedForm D · SEC · 3rd filing$135K
  • Federal grantHealth and Human S · Phase I · ACSS2 inhibition in treating Alcohol Abuse$260K
  • Federal grantHealth and Human S · Phase I · ACSS2 inhibition in treating Alcohol Abuse$260K
  • Private capital raisedForm D · SEC · 2nd filing$233K
  • Private capital raisedForm D · SEC · 1st filing$205K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 392 peers

Line = median

Biotech · Molecule

  • Federal grants#172 · top 44%
  • Granted patents#53 · top 14%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Thomas KimResearcherExecutive Officer, DirectorLinked by $571K in grants as PI
  • Eric SchultenoverDirectorNamed in SEC Form D filings
  • Michael DishowitzDirectorNamed in SEC Form D filings
  • Philipp MewsDirectorNamed in SEC Form D filings
  • Yi-Yen ChenDirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 5
  • PendingACSS2 Inhibitors And Methods Of Use ThereofUSPTOApplication 19321644
  • GrantedACSS2 Inhibitors And Methods Of Use ThereofUSPTOUS 12,441,689
  • PendingACSS2 Inhibitors And Methods Of Use ThereofUSPTOApplication 18936271
Show all 5 patent records
  • ACSS2 Inhibitors And Methods Of Use ThereofMar 26, 2026 · Application 19321644Pending
  • ACSS2 Inhibitors And Methods Of Use ThereofOct 14, 2025 · US 12,441,689Granted
  • ACSS2 Inhibitors And Methods Of Use ThereofJun 12, 2025 · Application 18936271Pending
  • ACSS2 Inhibitors And Methods Of Use ThereofNov 5, 2024 · US 12,133,852Granted
  • Imidazole 3-OXIDE Derivative Based ACSS2 Inhibitors And Methods Of Use ThereofJun 8, 2023 · Application 17922795Pending
  • METANOIA BIO LLCSimilar federal contract value in Biotech · null in contracts
  • Vesalius TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • THENDOR THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
  • Glycobia, Inc.Similar federal contract value in Biotech · null in contracts
  • LOXAGEN INC.Similar federal contract value in Biotech · null in contracts
  • PSYCHOGENICS, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .